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Background. 111In-DOTA-butylamino-NorBIRT (DANBIRT) is a novel radioligand which
binds to Leukocyte Function-associated Antigen-1 (LFA-1), expressed on inflammatory cells.
This study evaluated 111In-DANBIRT for the visualization of atherosclerotic plaque inflam-
mation in mice.
Methods and Results. ApoE2/2 mice, fed an atherogenic diet up to 20 weeks (n 5 10), were
imaged by SPECT/CT 3 hours post injection of 111In-DANBIRT (* 200 pmol, * 40 MBq).
Focal spots of 111In-DANBIRT were visible in the aortic arch of all animals, with an average
Target-to-Background Ratio (TBR) of 1.7 ± 0.5. In vivo imaging results were validated by
ex vivo SPECT/CT imaging, with a TBR up to 11.5 (range 2.6 to 11.5). Plaques, identified by Oil
Red O lipid-staining on excised arteries, co-localized with 111In-DANBIRT uptake as deter-
mined by ex vivo autoradiography. Subsequent histological processing and in vitro
autoradiography confirmed 111In-DANBIRT uptake at plaque areas containing CD68
expressing macrophages and LFA-1 expressing inflammatory cells. Ex vivo incubation of a
human carotid endarterectomy specimen with 111In-DANBIRT (* 950 nmol, * 190 MBq) for
2 hours showed heterogeneous plaque uptake on SPECT/CT, after which immunohistochemical
analysis demonstrated co-localization of 111In-DANBIRT uptake and CD68 and LFA-1
expressing cells.
Conclusions. Our results indicate the potential of radiolabeled DANBIRT as a relevant
imaging radioligand for non-invasive evaluation of atherosclerotic inflammation. (J Nucl
Cardiol 2018)
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Abbreviations
LFA-1 Leukocyte function-associated antigen-1
SPECT Single photon emission computed
tomography
CT Computed tomography
PET Positron emission tomography
18F-FDG 2-deoxy-2-18F-fluoro-D-glucose
DANBIRT 111In-DOTA-butylamino-NorBIRT
ApoE Apolipoprotein E
CEA Carotid endarterectomy
ROI Region of interest
TBR Target-to-background ratio
INTRODUCTION
Cardiovascular disease remains the major cause of
death worldwide.1 Most cardiovascular events are a
consequence of atherosclerosis, in which plaques form
due to chronic inflammation and lipid accumulation in
the vessel wall. Plaque progression can result in plaque
rupture and subsequent thrombus formation, potentially
leading to myocardial infarction or stroke. Timely
detection of plaque, before rupture, would allow targeted
treatment and prevention of a potentially life-threatening
cardiovascular event.
Inflammation is a major hallmark of atheroscle-
rosis and a consistent predictor of cardiovascular
risk.2,3 The recent Canakinumab Anti-inflammatory
Thrombosis Outcomes Study (CANTOS) trial showed
that reduction of inflammation in patients after
myocardial infarction could reduce the risk of new
adverse cardiovascular events in the future.4 Assess-
ment of the severity of inflammation in atherosclerosis
using biomarkers is cumbersome however. High-sen-
sitive C-reactive protein (hsCRP) is a prototypic
marker of inflammation and a strong independent
predictor for future cardiovascular events, yet is
influenced by risk factors such as hypertension,
smoking, and periodontal disease.5 Non-invasive visu-
alization of arterial inflammation may complement
biomarkers such as hsCRP in guiding treatment with
new anti-inflammatory drugs.
2-deoxy-2-18F-fluoro-D-glucose positron emission
tomography (18F-FDG PET) imaging is an established
method to non-invasively detect and quantify inflam-
mation within atherosclerotic plaques.6–8 FDG is a
glucose analogue, which accumulates in metabolically
active cells, including plaque-associated macrophages.
However, due to the high metabolic activity of myocar-
dial cells, 18F-FDG uptake by the myocardium might
hinder detection of coronary atherosclerotic plaques.
Furthermore, a necessary fasting period before imaging
and non-specific uptake limit the applicability of 18F-
FDG.9,10 These limitations warrant the search for
additional radioligands which might complement 18F-
FDG.
Development of atherosclerosis is initiated by
adhesion of monocytes as well as T lymphocytes to
the arterial endothelial surface, followed by their
migration into the subendothelial space.11 Leukocyte
Function-associated Antigen-1 (LFA-1), consisting of
CD11a and CD18 subunits, is an integrin cell-surface
receptor expressed on leukocytes. LFA-1 binds to
endothelial cells via interaction with Intercellular
Adhesion Molecule 1 (ICAM-1), and is involved in
transmigration of inflammatory cells to sites of
inflammation.12 LFA-1 was first identified as one of
the several adhesion molecules playing a role in
leukocyte trafficking, antigen presentation, and cell
activation. Immunohistochemical studies on animal
models of atherosclerosis have demonstrated the pres-
ence of LFA-1-positive cells in atherosclerotic
lesions.13,14 Therefore, LFA-1 may be a promising
imaging target for atherosclerotic plaque detection.
Recently, an allosteric inhibitor of LFA-115 was
chemically adapted for nuclear diagnostic and thera-
peutic purposes ((R)-1-(4-aminobutyl)-5-(4-
bromobenzyl)-3-(3,5-dichlorophenyl)-5-methylimidazo-
lidine-2,4-dione; butylamino-NorBIRT).16 Butylamino-
NorBIRT can be labeled with various radionuclides
for Single Photon Emission Computed Tomography
(SPECT) and PET imaging via a chelator (e.g.,
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic
acid (DOTA)), depicted in Figure 1. Indium-111-
DOTA-butylamino-NorBIRT (111In-DANBIRT) is
used for SPECT imaging and has been shown to
specifically bind LFA-1 on cultured human leukemic
and mouse lymphoma cells.16,17
The aim of this study was to examine the feasibility
of plaque detection using 111In-DANBIRT. To this end,
we studied in vivo uptake in ApoE-/- mice via SPECT/
Computed Tomography (CT) scanning, and established
its binding to human plaque material.
MATERIALS AND METHODS
Animals and Experimental Setup
Female ApoE -/- mice on a C57BL/6 J background
(n = 10) were purchased from Charles Rivers (Calco, Italy) at
6 weeks of age and were fed a high fat diet (0.3% cholesterol,
Altromin Spezialfutter GmbH & Co. KG, Lage, Germany)
ad libitum from 8 weeks of age onwards up to a maximum of
20 weeks. After SPECT/CT imaging, mice were sacrificed by
an overdose of inhalation anesthesia (isoflurane). All animal
experiments were approved by the institutional animal studies
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committee and were in accordance with Dutch animal ethical
legislation and the European Union Directive.
Radiolabeling
111In-DANBIRT (MW = 886.5 g/mole) (provided by J.P.
Norenberg) was radiolabeled with 111In (Covidien, Petten, The
Netherlands) with a specific activity of 200 MBq/nmol, as
previously described.18 Radiochemical purity ([ 90%) and
incorporation yield ([ 99%) were assessed using high-pressure
liquid chromatography and instant thin-layer chromatography
on silica gel. Quenchers (3.5 mM ascorbic acid, 3.5 mM
gentisic acid, 10 mM methionine) were added to prevent
radiolysis of the tracer.19
In vivo Imaging
Mice were injected intravenously in the tail vein
with * 40 MBq/200 pmol 111In-DANBIRT in 0.1% Bovine
serum albumin (BSA) in phosphate-buffered saline (PBS)
(injection volume of 150 lL) (n = 10). They were anes-
thetized (1.5 to 2% isoflurane) 2.5 h post injection, after which
they were injected with 100 lL CT-contrast agent (eXIA160,
Binito Biomedical Inc, Ottawa, ON, Canada; or Exitron nano
12000, Milteny Biotec, Bergisch-Gladach, Germany). Imme-
diately after contrast injection, a CT scan was performed
(17 min, 615 mA, 55 keV) followed by a SPECT scan (static
scan, 1 h, 2.0-mm pinhole collimator, 17 positions) on a hybrid
SPECT/CT scanner (VECTor, MILabs, Utrecht, The Nether-
lands) with a reported spatial resolution of 0.85 mm.20 SPECT
images were reconstructed using photopeak windows of 214-
262 and 152-185 keV, with a background window on either
side of the photopeak with a width of 2.5% of the correspond-
ing photopeak, and a pixel-based ordered subset expectation
maximization method (4 subsets and 30 iterations), a voxel
size of 0.8 mm3, and corrected for attenuation using the CT
data. A post-reconstruction 3-dimensional Gaussian filter was
applied (0.8 mm full width at half maximum). A blocking
study was performed by co-injection with a 1009 or 8509
excess of unlabeled DANBIRT in two mice.
Ex vivo Studies
After imaging, mice were euthanized and vasculature was
flushed with PBS via the left ventricle, followed by excision of
the aorta and carotid arteries. The arteries were cleaned from
visceral fat and connective tissue and stained for lipids (Oil red
O (ORO) according to standard protocol) to confirm plaque
presence. After staining, the arteries were scanned ex vivo
(CT: 5 min, 615 mA, 55 keV; SPECT: static scan, 30 min,
2.0-mm pinhole collimator) on a SPECT/CT scanner (VEC-
Tor, MILabs, Utrecht, The Netherlands). SPECT images were
reconstructed as described above. Subsequently, arteries were
used for ex vivo autoradiography (n = 4) or embedded in
tissue-tec and stored at – 80 C for histological analysis
(n = 6). To determine the biodistribution of 111In-DANBIRT
in ApoE-/- mice, selected organs were collected, weighed,
and measured for radioactivity in a gamma-counter (1480
Wizard, Gamma counter, Perkin Elmer). Radioactivity mea-
sured in the various tissues was expressed as percentage of
injected dose per gram (%ID/g). 111In-DANBIRT showed a
biodistribution pattern according to expectation, with limited
retention in major organs 24 hours post injection (Online
Resource 1). After * 3 weeks, arteries used for ex vivo
autoradiography were placed on a phosphor screen overnight
and read using a phosphor imager (Cyclone; Perkin Elmer).
Plaque signal was quantified as digital light units/mm2 (DLU/
mm2) using Optiquant software (Perkin Elmer), and compared
to non-diseased arterial signal in the same sample to calculate a
Target-to-Background Ratio (TBR).
Ex vivo Carotid Endarterectomy Study
To explore binding to human atherosclerotic plaques, we
incubated a human carotid endarterectomy (CEA, acquired
with informed consent and approved by the medical ethics
committee) sample with 111In-DANBIRT (* 950 pmol,
* 190 MBq) in 0.1% BSA in PBS for 2 hours. After
incubation, the specimen was washed in PBS and subsequently
scanned on the SPECT/CT scanner (CT: 5 min, 615 mA,
55 keV; SPECT: static scan, 30 min, 2.0-mm pinhole
Figure 1. Chemical structure of *R-DANBIRT. 1-(4-aminobutyl)-5-(4-bromobenzyl)-3-(3,5-
dichlorophenyl)-5-methylimidazolidine-2,4-dione-DOTA. R,radiometal.
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collimator). SPECT images were reconstructed as described
above. Hereafter, the specimen was cut in transverse slices of
1 mm. Even slices were used for autoradiography, odd slice for
histological evaluation. Histology was visually matched with
transverse views of the SPECT/CT scan, to correlate 111In-
DANBIRT uptake with locations of cells expressing LFA-1
and CD68.
Immunohistochemistry and In vitro
Autoradiography
Mouse aortic arch cryosections and human CEA cryosec-
tions (both 5 lm) were immunohistochemically stained with
anti-CD68, a pan-macrophage marker (human: 1:100, Abcam,
ab955; mouse: 1:100 Biorad, MCA1957), and anti-LFA-1
(human: 1:100 Biorad, MCA1848; mouse: 1:1, Pont et al.
198621) to assess co-localization of LFA-1 and CD68
(macrophage)-positive cells. In vitro autoradiography was
performed on mouse cryosections (10 lm) of aortic arch
adjacent to slides used for immunohistochemistry, by incubat-
ing slides for 1 hour with 80 lL 10-9 M 111In-DANBIRT.
Serially sectioned human CEA cryosections (10 lm) were
incubated for 1 h with 80 lL 10-9 M 111In-DANBIRT with or
without excess (10-6 M) unlabeled DANBIRT to determine
non-specific binding. Slides were exposed to phosphor screens
for 1 week and read using a phosphor imager (Cyclone; Perkin
Elmer). The autoradiograms of human CEA cryosections were
analyzed by drawing fixed regions of interests (ROIs) around
the sections using Optiquant software (Perkin Elmer). Signal
was quantified as DLU/mm2, after which blocked and
unblocked sections were compared using a student’s t test.
Quantification
SPECT data were analyzed with Vivoquant (Invicro) by
quantification of manually drawn regions of interests (ROIs)
based on contrast-enhanced CT. On in vivo scans, ROIs were
drawn in the aortic arch, vena cava inferior, and jugular vein.
ROIs on ex vivo scans were drawn in the aortic arch and non-
diseased artery in the descending aorta or common carotid
arteries. TBRs were calculated, and expressed as mean ±
standard deviation.
RESULTS
In vivo Mouse Plaque Imaging
In vivo SPECT/CT imaging 3 hours after intra-
venous injection of 111In-DANBIRT showed distinct
focal spots of radioactivity, corresponding to common
sites of plaque formation in the aortic arch of all animals
(Figure 2 and Online Resource 4), with an average TBR
of 1.7 ± 0.5. Uptake of 111In-DANBIRT at plaque
Figure 2. In vivo uptake of 111In-DANBIRT in atherosclerotic mice. In vivo contrast-enhanced
Computed Tomography (CT), Single Photon Emission Computed Tomography (SPECT), and
overlay images of ApoE-/- mouse thorax in coronal, sagittal, and transverse view. Scans were
made 3 h post injection. Exitron nano 12000 was used as contrast agent. 1 aortic arch; 2 right
common carotid artery; 3 left common carotid artery; 4 left subclavian artery. V, ventral; D, dorsal.
Arrowheads indicate radioactive hot spots (111In-DANBIRT uptake) in the aortic arch.
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locations in the carotid bifurcations was not above
background. Myocardial uptake was not above back-
ground in any of the animals. Co-injection of excess
unlabeled DANBIRT reduced uptake of 111In-DAN-
BIRT in plaque areas of the aortic arch to background
levels (Online Resource 2).
Ex vivo Validation
After in vivo imaging, arteries were excised and
scanned ex vivo. Focal uptake of 111In-DANBIRT in
the aortic plaques was evident (Figure 3A), with a TBR
up to 11.5 (range 2.6-11.5). To co-localize uptake to
plaque locations, we performed ex vivo autoradiogra-
phy and a lipid staining (ORO) on the excised arteries.
The ex vivo autoradiography showed high 111In-
DANBIRT uptake in regions in the aortic arch, arterial
branch points, descending aorta, and carotid bifurca-
tions, corresponding to plaque locations as indicated by
lipid staining (Figure 3A) with an average TBR of
19.0 ± 7.9. In vitro autoradiography and immunohisto-
chemistry of mouse aorta containing plaque
demonstrated 111In-DANBIRT binding to plaque areas
containing LFA-1-expressing inflammatory cells and
CD68-positive macrophages (Figure 3B). Binding of
111In-DANBIRT to human plaque cryosections could
be blocked by addition of an excess of unlabeled
DANBIRT (Online Resource 3).
Human Plaque Imaging
Incubation of a human CEA sample with 111In-
DANBIRT resulted in heterogeneous uptake of 111In-
DANBIRT seen as hot spots throughout the plaque in
SPECT/CT scans (Figure 4A, B, and Online Resource
5). Subsequent histological analysis of adjacent cryosec-
tions demonstrated co-localization of the hotspots of
111In-DANBIRT uptake with LFA-1-expressing inflam-
matory cells and CD68-positive macrophages
(Figure 4C–F).
Figure 3. Ex vivo validation of 111In-DANBIRT imaging of LFA-1. Frontal view of ex vivo CT,
SPECT, and overlay images of an excised artery of an ApoE-/- mouse, autoradiography (ARG)
and bright field photo of Oil Red O (ORO) stained, opened artery excised from another ApoE-/-
mouse, both injected with 111In-DANBIRT. 1 aortic arch; 2 right common carotid artery; 3 left
common carotid artery. Asterisks (*) indicate locations of needles used to pin down the artery.
Scale bar = 2 mm (panel A). In vitro autoradiography of 10-lm cryosection of mouse aortic arch.
Adjacent 5-lm cryosections immunohistochemically stained for LFA-1 and CD68 expression.
Scale bar = 100 lm (panel B), L = Lumen.
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DISCUSSION
In this study, we show the feasibility of in vivo
plaque detection using 111In-DANBIRT SPECT/CT
imaging of LFA-1. We demonstrated distinct focal
uptake in the aortic arch of all animals 3 hours after
intravenous injection of 111In-DANBIRT, despite the
small dimensions of murine arteries and plaques. This
uptake was related to the presence of lipid rich plaques
with inflammatory cells shown by ORO staining and
immunohistochemistry. Moreover, we showed uptake of
111In-DANBIRT in an excised human carotid plaque. In
addition, the presence of LFA-1-positive cells in
atherosclerotic plaque was confirmed by immunohisto-
chemistry. The finding that 111In-DANBIRT can detect
plaques in murine aortas (vessel diameter\ 1 mm)
point towards its possible applicability in human coro-
nary arteries which have a common diameter of around
3 mm22.
Various non-invasive imaging techniques are
explored for the early detection of atherosclerosis and
risk stratification of patients with cardiovascular disease,
using various target-ligand combinations that are asso-
ciated with atherosclerosis. The clinically most
frequently explored technique is 18F-FDG PET, which
has limits in regard to its specificity and myocardial
uptake. DANBIRT, in this study labeled with 111In,
solely binds to inflammatory cells and was not taken up
by the myocardium in our atherosclerotic mouse model.
As such, DANBIRT might surpass a limitation of 18F-
FDG. Moreover, DANBIRT might provide information
on different stages of plaque development as all leuko-
cytes express LFA-1. Furthermore, DANBIRT can be
labeled with 68Ga, which makes it suitable for PET
imaging and enhances its clinical applicability.
111In-DANBIRT signal was not visible by in vivo
nor ex vivo SPECT/CT imaging of the plaque in the
carotid artery bifurcations, whereas the more sensitive
ex vivo autoradiography did demonstrate uptake. This
could be due to a smaller plaque size and/or a lower
number, or a more diffuse distribution of inflammatory
cells, resulting in a signal below the detection threshold
of our SPECT system.
111In-DANBIRT exhibits specific uptake in plaques
in atherosclerotic mice. Uptake of 111In-DANBIRT
occurs in plaque areas that contain LFA-1 expressing
leukocytes and CD68-positive macrophages, indicating
specific targeting of LFA-1-positive cells. We conclude
that radiolabeled DANBIRT shows potential as a rele-
vant nuclear imaging ligand to detect atherosclerotic
inflammation. Upon confirmation of these findings in a
Figure 4. Ex vivo 111In-DANBIRT imaging of LFA-1 in a human atherosclerotic plaque. Bright
field photo of a Carotid Endarterectomy specimen. Yellow line indicates location of transverse view
of SPECT/CT scan in C, autoradiography of 1 mm thick transverse slide in D, and adjacent
histologic sections in E and F. Scale bar = 10 mm (A). SPECT/CT imaging shows heterogeneous
uptake of 111In-DANBIRT. Calcified regions of the plaque are visible in bright white in the CT
views. Pins used as landmarks are indicated by asterisks (*). Coronal (B), and transverse views (C)
of SPECT/CT scan. Ex vivo autoradiography image (D). LFA-1 expression is visible in a slide
adjacent to D, co-localizing with areas of high 111In-DANBIRT uptake. Inset shows overview of the
histological section; asterisk shows location of zoomed area. Scale bar = 100 lm (E). CD68
expressing macrophages are present in an adjacent cryosection. Inset shows overview of the
histological section; asterisk shows location of zoomed area. Scale bar = 100 lm (F), L = Lumen.
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patient population, this imaging tool may be used to
improve risk assessment of cardiovascular disease by
visualizing inflammation and for individualizing specific
anti-inflammatory drug therapy.
NEW KNOWLEDGE GAINED
The novel LFA-1 targeting radioligand DANBIRT
detects inflammation in vivo in atherosclerotic plaques in
anApoE-/-mousemodel. DANBIRTuptake correlates to
the presence of CD68 expressing macrophages and LFA-1
expressing inflammatory cells in the atherosclerotic pla-
que. In addition, ex vivo uptake of DANBIRT in a human
carotid plaque correlates to the presence of CD68 express-
ing macrophages and LFA-1 expressing inflammatory
cells, suggesting the potential of DANBIRT for non-
invasive imaging of atherosclerotic plaque inflammation.
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